Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Eastman Chemical Company

Other

Richter Gedeon Vegyeszeti Gyar Rt

Consortium Fur Elektrochemische Industrie Gmbh

Reanal Finomvegyszergyar

Istituto Biochimico Italiano Giovanni Lorenzini S.p.a.

Therabel Industries, S.a.

Chinoin Gyogyszervegyeszeti Gyar

Forte Fotokemial Idpar

Novartis Ag

Novartis Pharma Gmbh

Jozsef Szejtli

Lajos Szente

Bela Zsadon

Eva Fenyvesi

Katalin Marmarosi

Agnes Stadler Nee Szoke

Zsuzsanna Budai

Gabriella Pap Nee Imrenyi

Magda Tetenyi Nee Erdosi

Charles Michael Buchanan

Agnes Horvath

Dezso Korbonits

Juanelle Little Lambert

Gabor Horvath

Peter Tetenyi

Jozsef Gaal

Katalin Kaloy

Ferenc Tudos

Shannon Eugene Large

Laszlo Jicsinszky

Ildiko Jodal

Steven N Falling

Gabor Seres

Maria Vikmon Nee Kiraly

Iren Munkacsi

Istvan Hermecz

Gabor Kovacs

Sandor Virag

Jozsef Knoll

Agoston David

Pal Kiss

Tibor Szabo

Istvan Stadler

Tamas Szuts

Sandor Zoltan

Gyorgy Cseh

Vera Gergely

Enrico Bosone

Jeno Marton

Mihaly Nogradi

Sandor Antus

Laszlo Institoris

Sandor Piukovich

Umberto Valcavi

Laszlo Boross

Miklos Jarai

Agnes Gottsegen

Ivan Daroczi

Istvan Turcsan

Eva Udvardy Nagy Nee Cserey Pechany

Andras Kerekes

Zoltan Vargay

Laszlo Papp

Istvan Bartho

Jeno Bernath

Andras Liptak

Pal Nanasi

Maria Vikmon

Wilfried Wachter

Erzsebet Radvany Nee Hegedus

Viktor Weiszfeiler

Lorant Janossy

Gabor Hantos

Maria Trinn

Miklos Szucs

Maria Szilasi

Marta Kiniczky

Eva Dobos

Andrasne Vikmon

Eva Dosa

Edomer Tassonyi

Zsuzsanna Nagy Nee Biro

Nee Otta Horvath

Ildiko Wagner Nee Kohary

Balazs Antal

Peter Fugedi

Lili Kandra

Lajos Decsei

Marta Tardy Nee Lengyel

Marta Balazs Nee Czurda

Ilona Habon

Gyorgy Kormoczy

Zsuzsa Vida

Magdolna Szejtli Nee Rengei

Agnes Stadler

Zsuzsa Furst

Bela Szanjani

Katalin Ivony Nee Kaldive

Eva Fenyves

Vincenzo Monterosso

Maria Szigetvari Nee Gabanyi

Andrea Gerloczy

Roberto Caponi

Istvanne Palotas

Julia Szeman

Erzsebet Banky Nee Elod

Hermecz: Istvan

Maaria Vikmon

Joseph Geczy

Julianna Szeman

This invention relates to new cyclodextrin derivatives, processes for producing these cyclodextrin derivatives, and inclusion complexes comprised of the new cyclodextrin derivatives and guest molecules, as well as methods of making such materials and related materials and methods of using the same.

Composition containing mixture of dihydroxybutane sulfonates

Cyclodextrin sulfonates, guest inclusion complexes methods of making the same and related materials

This invention provides inclusion complexes of Taxol ((2aR-(a&agr;,4&bgr;,4&agr;&bgr;,6&bgr;,9&agr;(&agr;R*,&bgr;S*),11&agr;,12&agr;,12a&agr;,12b&agr;))-&bgr;-(benzoylamino)-&agr;-hydroxy-benzene-propanoic acid 6,12-b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclo-deca-(3,4)-benz-(1,2-b)-oxeth-9-yl-ester)) or Taxotere (butoxycarbonyl-10-desacetyl-N-debenzoyl-Taxol) or Taxus extracts formed with a cyclodextrin derivative and a co-solvent. This invention relates to pharmaceutical composition with increased water-solubility and stability. This invention provides the process for the preparation of an inclusion complex of Taxol or Taxotere or a brevifolia extract of Taxus formed with a cyclodextrin derivative and a co-solvent. This invention relates to pharmaceutical composition, containing as active ingredient an effective amount of an inclusion complex of Taxol or Taxotere or a Taxus brevifolia extract formed with a cyclodextrin derivative, preferably heptakis-2,6-0 dimethyl-&bgr;-cyclodextrin, random methylated &bgr;-cyclodextrin, succinylmethyl-&bgr;-cyclodextrin and a co-solvent together with usual filling, diluting and other auxiliaries generally used in the pharmaceutical industry.

Complexes and their compositions

SIN-1A cyclodextrin inclusion complexes

Inclusion complexes of N-ethoxycarbonyl 1-3-morpholino-sydnonimine or

Inclusion complexes of 3-morpholino-sydnonimine or its salts or its

The invention relates to inclusion complexes of Silybinin with a cyclodextrin selected from the group consisting of .alpha.-, .beta.- and .gamma.-cyclodextrin and a suitable derivative thereof and to the method for the preparation thereof. The inclusion complexes of Silybinin showed a highly improved bioavailability in comparison to Silybinin which makes them particularly interesting in the treatment of various hepatotoxic conditions.

Inclusion complexes with silybinin, their preparation and pharmaceutical

The invention relates to novel partially methylated carboxyacyl-cyclodextrins of the general formula (I), ##STR1## wherein A means the cyclodextrin skeleton of the general formula (II) ##STR2## containing the substituents in the position labelled by the wavy line; W stands for an alkylene, alkenylene or arylene group or the substituted derivatives thereof;

Methylated cyclodextrin type compounds and process for preparing same

The invention relates to fungicidal plant protecting composition comprising 3-90% by weight of a fungicidal active ingredient in admixture with 1-90% by weight of cyclodextrin and optionally with usual auxiliary agents. The advantage of the synergistic composition of the present invention is that identical fungicidal effect can be achieved with a significantly lower active ingredient dosage and this decreases the costs involved with the active ingredient and reduces the risks of environmental pollution as well.

Process for enhancing the activity of plant protecting agents by using

The invention relates to a process for the preparation of high-purity gamma- and alpha-cyclodextrin starting from a starch substrate of low reducing capacity, partially hydrolysed with alpha-amylase. According to the invention a starch substrate of low reducing capacity partially hydrolysed with alpha-amylase is converted with cyclodextrin glucosyl transferase, after the addition of an aliphatic ketone of the formula R.sub.1 COR.sub.2, in which R.sub.1 and R.sub.2 stand for a straight or branched chained alkyl group having from 1 to 6 carbon atoms, and/or a phenol derivative of the formula R.sub.3 R.sub.4 PheOH, wherein R.sub.3 and R.sub.4 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.3 and R.sub.4 together form phenyl group, Phe stand for phenyl group, OH is hydroxyl and/or a benzene derivative of the formula R.sub.5 R.sub.6 Phe, wherein R.sub.5 and R.sub.6 are hydrogen, alkyl having from 1 to 4 carbon atoms, or R.sub.5 and R.sub.6 together form phenyl group, Phe is phenyl, as a precipitating agent, and if desired, alpha- and/or gamma-cyclodextrin is isolated from the conversion mixture in a crude form, or after further purification, in a pure form.

Process for the preparation of high-purity gamma- and alpha-cyclodextrins

The invention relates to the inclusion complexes of 7-isopropoxy-isoflavone formed with cyclodextrin or cyclodextrin derivatives as well as to the pharmaceutical compositions containing these inclusion complexes as active ingredient. The invention further relates to the preparation of the new inclusion complexes. The new inclusion complex according to the invention shows higher dissolution and resorption properties as compared to the active ingredient administered per se.

Inclusion complex of 7-isopropoxy-isoflavon formed with cyclodextrin,

The invention relates to a method of promoting the fat digestion and absorption, which comprises orally administering to an animal subject a partially methylated-.beta.-cyclodextrin optionally together with pharmaceutically acceptable auxiliary and/or additive materials.

Bile-substituting method of treatment for the promotion of fat digestion

The invention relates to a process for removing nucleic acids and purine bases from gelatine by (a) adding cyclodextrin bead polymer having a particle size of 20 to 600 .mu., a cyclodextrin content of 30 to 70% and a polyvinyl alcohol content of 0.3 to 0.5% to the gelatin solution in a weight ratio of 1:1 to 10:1 calculated on the amount of the gelatin then filtering off the cyclodextrin polymer or (b) passing the gelatin solution through a cyclodextrin bead polymer column, whereby the amount of the gelatin is 5 to 50% of the weight of the column charge, then eluting the nucleic acids and the purine bases from the cyclodextrin bead polymer.

Process for removing nucleic acids and purine bases from gelatin

A new method is disclosed for the treatment and prevention of gastrointestinal ulcers or erosions which comprises the administration of a pharmaceutically effective amount of a PGI.sub.2 methyl ester-beta cyclodextrin complex to a patient in need of said treatment wherein the amount of the PGI.sub.2 methyl ester constitutes 1 to 15% by weight of the complex.

Method of treating ulcers and erosions in the gastrointestinal system

2,6-di-O-methyl-beta-cyclodextrin complexes of compounds of the formula (1a) ##STR1## wherein R.sup.2' stands for C.sub.1 to C.sub.12 alkyl or a group of the formula ##STR2## in which R.sup.11 is C.sub.1 to C.sub.4 alkyl;

Dibenzo[bd]pyran derivatives, process for the preparation thereof and

Growing community of inventors

Budapest, Hungary

Jozsef Szejtli